Plasma Citrulline in Preterm With NEC

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04313933

Acronym

NEC

Enrollment

Registered

2020-03-18

Start date

2019-03-12

Completion date

2020-02-15

Last updated

2020-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Citrulline, NEC

Brief summary

Aim of study

Detailed description

Introduction

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Days to 30 Days

Inclusion criteria

* preterm neonates \< 35 weeks Preterm neonates\< 2kg Preterm neonates diagnosed with necrotizing enterocolitis

Exclusion criteria

* renal dysfunction Inborn error of metabolism Congenital malformation

Design outcomes

Primary

Measure	Time frame	Description
plasma citrulline as a marker of Necrotizing enterocolitis diagnosis	1 Year	Compare plasma citrulline in NEC and comparing it with properly matched healthy neonates

Secondary

Measure	Time frame	Description
Citrulline as a marker of intestinal recovery	1 year	Follow up plasma citrulline level after initiation of feeding

Countries

Egypt

Outcome results